Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 139

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 139
---
 equal to the Legacy CERo     
 option exercise price divided by the Exchange Ratio.                                                                                  |

| 7. | Each Legacy                                                                                                                      
 CERo warrant was converted into a warrant to acquire a number of shares of Class A Common Stock obtained by dividing the warrant 
 as-if-exercised liquidation preference by $10.00, with the exercise price equal to the total Legacy CERo warrant exercise amount 
 divided by the number of shares of Common Stock issuable upon exercise.                                                          |

| 8. | The Convertible                                                                                                              
 Bridge Notes automatically converted into shares of Series A Preferred Stock, at a conversion price equal to $750 per share. |

CERo issued, transferred
from the Sponsor, or reserved for issuance an aggregate of 8.4 million shares of Class A Common Stock to the holders of Legacy CERo common
stock and Legacy CERo preferred stock or reserved for issuance upon exercise of Legacy CERo options or warrants as consideration in the
Business Combination. In connection with the Business Combination, PBAX changed its name to “CERo Therapeutics Holdings, Inc.”

The unaudited pro forma
condensed combined financial information has been prepared using the assumptions below:

On June 4, 2023, Legacy
CERo entered into a bridge financing agreement (the “Bridge Financing”) in anticipation of Legacy CERo completing the Business
Combination with PBAX pursuant to a definitive Business Combination Agreement. On June 6, 2023, Legacy CERo sold the Convertible Bridge
Notes with an aggregate principal amount of $605,230 to certain eligible participants. The Convertible Bridge Notes were automatically
converted (principal and accrued interest) upon the Business Combination into an aggregate of 630 shares of Series A Preferred Stock
at conversion rate of $1,000 per share, and all of the Convertible Bridge Notes were retired.

An additional 1,000,000
shares of restricted Common Stock were issued to select Legacy CERo stockholders and Convertible Bridge Note investors and a corresponding
1,000,000 shares of Common Stock held by the Sponsor have been restricted. Upon the filing of an investigational new drug (“IND”)
application with the FDA, the restrictions upon the shares of Common Stock issued to such Legacy CERo stockholders and Convertible Bridge
Note investors will be removed, and the shares of Common Stock held by the Sponsor will be retired. Should CERo fail to file an IND with
the FDA,